Success and problems of long-term levodopa therapy in Parkinson's disease
- PMID: 64868
- DOI: 10.1016/s0140-6736(77)91146-1
Success and problems of long-term levodopa therapy in Parkinson's disease
Abstract
The patient with Parkinson' disease on chronic levodopa therapy, like the diabetic on insulin, is dependent on the drug. Like the diabetic, the patients with Parkinson's disease may run into problems during long-term treatment. Two have emerged as frequent and serious, an insidious and progressive loss of benefit and the appearance of progessively more severe fluctuations in disability. It is concluded that progression of the underlying pathology of the disease is probably responsible. Discovery of the exact causes for loss of benefit may provide a rational basis for new therapy.
Similar articles
-
The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.Drugs. 1998;55 Suppl 1:1-9. doi: 10.2165/00003495-199855001-00001. Drugs. 1998. PMID: 9483164 Review.
-
[Current problems of drug treatment of Parkinson disease].Neurol Neurochir Pol. 1980 Jul-Aug;14(4):427-35. Neurol Neurochir Pol. 1980. PMID: 7412998 Polish. No abstract available.
-
Problems of levodopa treatment.Clin Neurol Neurosurg. 1984;86(3):196-206. doi: 10.1016/0303-8467(84)90196-3. Clin Neurol Neurosurg. 1984. PMID: 6091967
-
Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.Prog Brain Res. 2008;172:479-94. doi: 10.1016/S0079-6123(08)00923-0. Prog Brain Res. 2008. PMID: 18772047 Review.
-
Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.Mov Disord. 2008;23 Suppl 3:S613-22. doi: 10.1002/mds.22061. Mov Disord. 2008. PMID: 18781663 Review.
Cited by
-
Mass Spectrometry Analysis of Neurotransmitter Shifting during Neurogenesis and Neurodegeneration of PC12 Cells.Int J Mol Sci. 2024 Sep 27;25(19):10399. doi: 10.3390/ijms251910399. Int J Mol Sci. 2024. PMID: 39408728 Free PMC article.
-
A commentary on: "A 12-year population-based study of freezing of gait in Parkinson's disease".Front Aging Neurosci. 2015 Jun 2;7:106. doi: 10.3389/fnagi.2015.00106. eCollection 2015. Front Aging Neurosci. 2015. PMID: 26082717 Free PMC article. No abstract available.
-
Long-Term Home-Monitoring Sensor Technology in Patients with Parkinson's Disease-Acceptance and Adherence.Sensors (Basel). 2019 Nov 26;19(23):5169. doi: 10.3390/s19235169. Sensors (Basel). 2019. PMID: 31779108 Free PMC article.
-
Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.Drugs Aging. 2004;21(11):687-709. doi: 10.2165/00002512-200421110-00001. Drugs Aging. 2004. PMID: 15323576 Review.
-
Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease.J Pharmacokinet Pharmacodyn. 2005 Aug;32(3-4):459-84. doi: 10.1007/s10928-005-0055-x. J Pharmacokinet Pharmacodyn. 2005. PMID: 16320101 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources